Development of Web-Based Nomograms to Predict Treatment Response and Prognosis of Epithelial Ovarian Cancer
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose Discovery of models predicting the exact prognosis of epithelial ovarian cancer (EOC) is necessary as the first step of implementation of individualized treatment. This study aimed to develop nomograms predicting treatment response and prognosis in EOC. Materials and Methods We comprehensively reviewed medical records of 866 patients diagnosed with and treated for EOC at two tertiary institutional hospitals between 2007 and 2016. Patients’ clinicopathologic characteristics, details of primary treatment, intra-operative surgical findings, and survival outcomes were collected. To construct predictive nomograms for platinum sensitivity, 3-year progression-free survival (PFS), and 5-year overall survival (OS), we performed stepwise variable selection by measuring the area under the receiver operating characteristic curve (AUC) with leave-one-out cross-validation. For model validation, 10-fold cross-validation was applied. Results The median length of observation was 42.4 months (interquartile range, 25.7 to 69.9 months), during which 441 patients (50.9%) experienced disease recurrence. The median value of PFS was 32.6 months and 3-year PFS rate was 47.8% while 5-year OS rate was 68.4%. The AUCs of the newly developed nomograms predicting platinum sensitivity, 3-year PFS, and 5-year OS were 0.758, 0.841, and 0.805, respectively. We also developed predictive nomograms confined to the patients who underwent primary debulking surgery. The AUCs for platinum sensitivity, 3-year PFS, and 5-year OS were 0.713, 0.839, and 0.803, respectively. Conclusion We successfully developed nomograms predicting treatment response and prognosis of patients with EOC. These nomograms are expected to be useful in clinical practice and designing clinical trials.
Abstract
Purpose Discovery of models predicting the exact prognosis of epithelial ovarian cancer (EOC) is necessary as the first step of implementation of individualized treatment. This study aimed to develop nomograms predicting treatment response and prognosis in EOC. Materials and Methods We comprehensively reviewed medical records of 866 patients diagnosed with and treated for EOC at two tertiary institutional hospitals between 2007 and 2016. Patients’ clinicopathologic characteristics, details of primary treatment, intra-operative surgical findings, and survival outcomes were collected. To construct predictive nomograms for platinum sensitivity, 3-year progression-free survival (PFS), and 5-year overall survival (OS), we performed stepwise variable selection by measuring the area under the receiver operating characteristic curve (AUC) with leave-one-out cross-validation. For model validation, 10-fold cross-validation was applied. Results The median length of observation was 42.4 months (interquartile range, 25.7 to 69.9 months), during which 441 patients (50.9%) experienced disease recurrence. The median value of PFS was 32.6 months and 3-year PFS rate was 47.8% while 5-year OS rate was 68.4%. The AUCs of the newly developed nomograms predicting platinum sensitivity, 3-year PFS, and 5-year OS were 0.758, 0.841, and 0.805, respectively. We also developed predictive nomograms confined to the patients who underwent primary debulking surgery. The AUCs for platinum sensitivity, 3-year PFS, and 5-year OS were 0.713, 0.839, and 0.803, respectively. Conclusion We successfully developed nomograms predicting treatment response and prognosis of patients with EOC. These nomograms are expected to be useful in clinical practice and designing clinical trials.
참고문헌 (27)
- Siegel RL, "Cancer statistics, 2017", CA Cancer J Clin, 67, pp.7~30 (2017)
- "SEER cancer statistics review, 1975-2014" (2017)[URL]
- Global Burden of Disease Cancer Collaboration, "The global burden of cancer 2013", JAMA Oncol, 1, pp.505~527 (2015)
- 임명철, "Incidence of cervical, endometrial, and ovarian cancer in Korea, 1999-2010", Journal of Gynecologic Oncology, 24(4), pp.298~302 (2013), 대한부인종양학회
- Smith LH, "Romano PS. Ovarian cancer: can we make the clinical diagnosis earlier?", Cancer, 104, pp.1398~1407 (2005)
- Cho KR, "Ovarian cancer", Annu Rev Pathol, 4, pp.287~313 (2009)
- Bristow RE, "Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era : a metaanalysis", J Clin Oncol, 20, pp.1248~1259 (2002)
- Chi DS, "Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer : a change in surgical approach", Gynecol Oncol, 94, pp.650~654 (2004)
- Wimberger P, "Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease : an exploratory analysis of the AGO-OVAR(Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group)", Ann Surg Oncol, 17, pp.1642~1648 (2010)
- Cannistra SA, "Cancer of the ovary", N Engl J Med, 351, pp.2519~2529 (2004)
- Teramukai S, "PIEPOC: a new prognostic index for advanced epithelial ovarian cancer--Japan Multinational Trial Organization OC01-01", J Clin Oncol, 25, pp.3302~3306 (2007)
- Chi DS, "Nomogram for survival after primary surgery for bulky stage IIIC ovarian carcinoma", Gynecol Oncol, 108, pp.191~194 (2008)
- Gerestein CG, "The prediction of progressionfree and overall survival in women with an advanced stage of epithelial ovarian carcinoma", BJOG, 116, pp.372~380 (2009)
- Barlin JN, "Nomogram for predicting 5-year disease-specific mortality after primary surgery for epithelial ovarian cancer", Gynecol Oncol, 125, pp.25~30 (2012)
- Lee CK, "Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer", Br J Cancer, 105, pp.1144~1150 (2011)
- Lee CK, "A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer", Ann Oncol, 24, pp.937~943 (2013)
- Previs RA, "A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy", Gynecol Oncol, 132, pp.531~536 (2014)
- 백이선, "Nomograms Predicting Platinum Sensitivity, Progression-Free Survival, and Overall Survival Using Pretreatment Complete Blood Cell Counts in Epithelial Ovarian Cancer", Cancer Research and Treatment, 49(3), pp.635~642 (2017), 대한암학회
- Foote J, "Predicting 6-and 12-month risk of mortality in patients with platinum-resistant advanced-stage ovarian cancer : prognostic model to guide palliative care referrals", Int J Gynecol Cancer, 28, pp.302~307 (2018)
- Eisenhauer EA, "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)", Eur J Cancer, 45, pp.228~247 (2009)
- Rustin GJ, "Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)", Int J Gynecol Cancer, 21, pp.419~423 (2011)
- Heagerty PJ, "Survival model predictive accuracy and ROC curves", Biometrics, 61, pp.92~105 (2005)
- Mantovani A, "Cancer-related inflammation", Nature, 454, pp.436~444 (2008)
- Pujade-Lauraine E, "Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer : The AURELIA open-label randomized phase III trial", J Clin Oncol, 32, pp.1302~1308 (2014)
- Aghajanian C, "OCEANS : a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer", J Clin Oncol, 30, pp.2039~2045 (2012)
- Coleman RL, "Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer(NRG Oncology", Gynecologic Oncology Group study GOG-0213) : a multicentre, open-label, randomised, phase 3 trial, 2017, pp.18, 779~791
- Pujade-Lauraine E, "Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1", 2 mutation(SOLO2, Lancet Oncol, pp.2017, 18[DOI]